The official launch date of Pemigatinib in China

Pemigatinib (Pemigatinib) is an oral drug targeting specific molecular targets. It is mainly used for the treatment of advanced cholangiocarcinoma (CCA) and myeloid/lymphoid tumors associated with FGFR1 rearrangement. The domestic drug regulatory authorities approved the drug for marketing on March 29, 2022. This is an important node for Chinese patients to legally obtain this innovative targeted drug. It is worth noting that after pemetinib was launched, it was not covered by medical insurance in China, so patients need to pay for the drug out of pocket when purchasing it.

The domestically marketed pemetinib will remain consistent with the overseas approved indications and is mainly targeted at patients with locally advanced or metastatic cholangiocarcinoma who have failed previous treatment or are unresectable. It is also suitable for adult patients with relapsed or refractory bone marrow/lymphoid tumors with FGFR1 rearrangements. The approval of the drug provides new treatment options for relevant domestic patients, especially for patients who have limited response to conventional chemotherapy or who are inoperable. The launch of pemetinib is of great significance.

During clinical use, doctors will develop an individualized medication plan based on the patient's specific disease type, genotyping results, and previous treatment history. For patients with cholangiocarcinoma, the recommended dose is 13.5 mg once a day, taken continuously for 14 days, and then stopped for 7 days to enter a 21-day cycle; for patients with FGFR1-rearranged myeloid/lymphoid tumors, a regimen of continuous oral administration once a day is adopted until disease progression or intolerable side effects occur. This precisely targeted medication model enables pemetinib to achieve a good balance between disease control and side effect management.

In general, pemetinib has brought new treatment opportunities to patients with cholangiocarcinoma and specific hematological tumors since its approval in China in 2022. Although it has not yet been included in medical insurance, its precise targeted treatment advantages make it irreplaceable in clinical practice.

Reference materials:https://go.drugbank.com/drugs/DB15102